Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926222 | 0.88 | MLYCD (0.64) | KMT2AMEN1ALDH1A1GAALMNA | |
| SCHEMBL6929810 | 0.85 | MEN1 (0.59) | KMT2AMEN1ALDH1A1L3MBTL1GAA | |
| SCHEMBL2610071 | 0.85 | MEN1 (0.85) | KMT2AMEN1ALDH1A1L3MBTL1GAA | |
| SCHEMBL16082990 | 0.85 | MEN1 (0.85) | KMT2AMEN1ALDH1A1L3MBTL1GAA | |
| SCHEMBL6931395 | 0.82 | TP53 (0.52) | KMT2AMEN1ALDH1A1TP53GAA | |
| SCHEMBL6931350 | 0.81 | TP53 (0.60) | KMT2AMEN1ALDH1A1TP53LMNA | |
| SCHEMBL6925253 | 0.79 | TP53 (0.58) | KMT2AMEN1ALDH1A1TP53LMNA | |
| SCHEMBL17658572 | 0.78 | MEN1 (0.74) | KMT2AMEN1ALDH1A1L3MBTL1GAA | |
| SCHEMBL25894434 | 0.78 | MEN1 (0.78) | KMT2AMEN1ALDH1A1L3MBTL1GAA | |
| SCHEMBL19074860 | 0.78 | MEN1 (0.78) | KMT2AMEN1ALDH1A1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | claimed |
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP8, MMP13 | KMT2A 4700/4885MEN1 3055/4885ALDH1A1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.